SYK Stryker Corporation - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
SYK Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$363.78
Analyst Target
$427.39
+17.5%
Upside
52W High
$406.19
52W Low
$329.16
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a weak fundamental health with a Piotroski F-Score of 4/9, indicating marginal stability, and the absence of an Altman Z-Score prevents a full solvency risk assessment. Despite solid profitability metrics like a 65.05% gross margin and 22.27% operating margin, the stock appears significantly overvalued with a P/E of 47.80 versus a Graham Number of $98.76 and intrinsic value of $85.23, implying a substantial premium. Earnings growth has sharply declined, with YoY EPS down 22.6% and Q/Q EPS falling 29.1%, while insider selling of $261.57M in the last six months signals strong bearish sentiment. Analysts maintain a 'buy' recommendation with a $427.39 target, but recent earnings misses and deteriorating momentum suggest over-optimism.
Key Strengths
High gross margin (65.05%) reflecting strong pricing power and cost control in medical devices
Solid operating margin (22.27%) indicating efficient core operations
Revenue growth of 10.20% YoY outpaces sector average of 9.80%
Healthy current ratio of 1.85, suggesting adequate short-term liquidity
Low debt/equity ratio of 0.79, below sector average of 0.92, indicating conservative capital structure
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health with recent deterioration in profitability and leverage trends
Extremely high valuation: P/E of 47.80 vs Graham Number implying fair value below $100, suggesting massive overpricing
Earnings growth collapse: YoY EPS down 22.6% and Q/Q EPS down 29.1%, reversing prior growth trajectory
Consistent earnings misses: 3 out of last 4 quarters missed estimates with an average surprise of -12.34%
Strong insider selling: $261.57M in net sales over 6 months, including large director sale of 520,000 shares
AI Fair Value Estimate
Based on comprehensive analysis
$98.76
-72.9% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare SYK against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning SYK from our newsroom.
Newest → oldest
No matching news yet.